In the phase I/II trial, high doses of membrane-bound IL-21 (mb-IL21) ex vivo expanded donor-derived NK cells (NCT01904136) resulted in lower 2-year relapse rate with better disease-free survival (DFS) in patients suffering from various myeloid malignancies (204). The gene discussed is IL21; the disease is myeloid neoplasm.